NZ813867A - Adam6 mice - Google Patents

Adam6 mice

Info

Publication number
NZ813867A
NZ813867A NZ813867A NZ81386712A NZ813867A NZ 813867 A NZ813867 A NZ 813867A NZ 813867 A NZ813867 A NZ 813867A NZ 81386712 A NZ81386712 A NZ 81386712A NZ 813867 A NZ813867 A NZ 813867A
Authority
NZ
New Zealand
Prior art keywords
mouse
human
gene segments
cell
genome
Prior art date
Application number
NZ813867A
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ813867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from NZ797720A external-priority patent/NZ797720B2/en
Publication of NZ813867A publication Critical patent/NZ813867A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/22—Heating, cooling or ventilating devices the heat source being other than the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
NZ813867A 2011-02-25 2012-02-24 Adam6 mice NZ813867A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
NZ797720A NZ797720B2 (en) 2012-02-24 ADAM6 mice

Publications (1)

Publication Number Publication Date
NZ813867A true NZ813867A (en) 2026-02-27

Family

ID=45998616

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ813867A NZ813867A (en) 2011-02-25 2012-02-24 Adam6 mice
NZ731926A NZ731926A (en) 2011-02-25 2012-02-24 Adam6 mice
NZ776770A NZ776770A (en) 2011-02-25 2012-02-24 Adam6 mice

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ731926A NZ731926A (en) 2011-02-25 2012-02-24 Adam6 mice
NZ776770A NZ776770A (en) 2011-02-25 2012-02-24 Adam6 mice

Country Status (31)

Country Link
US (12) US8642835B2 (enExample)
EP (7) EP2813573B1 (enExample)
JP (8) JP2014507137A (enExample)
KR (1) KR101387377B1 (enExample)
CN (2) CN103429746B (enExample)
AU (6) AU2012243291B2 (enExample)
BR (1) BR112013021771B1 (enExample)
CA (1) CA2820824A1 (enExample)
CY (5) CY1116301T1 (enExample)
DE (5) DE14154967T1 (enExample)
DK (6) DK2550363T3 (enExample)
ES (6) ES2532487T3 (enExample)
FI (3) FI2578688T4 (enExample)
HR (5) HRP20230526T1 (enExample)
HU (5) HUE062552T2 (enExample)
IL (4) IL226727A (enExample)
IN (1) IN2013CN07629A (enExample)
LT (4) LT2738259T (enExample)
ME (3) ME03732B (enExample)
MX (3) MX375115B (enExample)
MY (1) MY172713A (enExample)
NZ (3) NZ813867A (enExample)
PL (5) PL4067496T3 (enExample)
PT (5) PT2738259T (enExample)
RS (5) RS53880B1 (enExample)
RU (2) RU2722373C2 (enExample)
SG (4) SG10201405135RA (enExample)
SI (5) SI2578688T2 (enExample)
SM (5) SMT201900581T1 (enExample)
WO (1) WO2012141798A1 (enExample)
ZA (1) ZA201305998B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
KR102306967B1 (ko) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
PT3865581T (pt) * 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
KR20140082824A (ko) * 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PT3527070T (pt) 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
NZ810648A (en) * 2012-02-01 2025-11-28 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
HK1200271A1 (en) 2012-03-16 2015-08-07 瑞泽恩制药公司 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
EP3912464A1 (en) * 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
AU2014214863B2 (en) 2013-02-06 2019-03-21 Duke University B cell lineage based immunogen design with humanized animals
MY185881A (en) 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
PL2967012T3 (pl) * 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
CN106255410B (zh) * 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
IL302725A (en) 2016-01-13 2023-07-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
SG11201806427WA (en) 2016-02-16 2018-08-30 Regeneron Pharma Non-human animals having a mutant kynureninase gene
US20170332610A1 (en) * 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
PT4082334T (pt) 2016-11-04 2025-05-21 Regeneron Pharma Animais não humanos possuindo um lócus da cadeia leve lambda de immunoglobulina geneticamente modificada
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
TW202438676A (zh) 2017-12-05 2024-10-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
US20210000088A1 (en) 2018-03-21 2021-01-07 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
DK3785536T4 (da) * 2019-08-28 2025-10-27 Trianni Inc Adam6-knockin-mus
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
KR20230124594A (ko) 2020-12-23 2023-08-25 리제너론 파마슈티칼스 인코포레이티드 막관통 단백질 및 이를 생산하는 세포에 결합하는 항체를 수득하는 방법
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2022225985A1 (en) 2021-04-20 2022-10-27 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
KR20250150011A (ko) 2023-02-13 2025-10-17 리제너론 파마슈티칼스 인코포레이티드 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
IL325400A (en) 2023-07-10 2026-02-01 Regeneron Pharma Anti-human CACNG1 antibody-drug conjugates and their uses
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
JP2026508379A (ja) * 2023-09-15 2026-03-10 賽業（蘇州）生物科技有限公司 抗体を製造するための遺伝子改変マウスおよびその作製方法
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2149025A1 (en) * 1992-12-01 1994-06-09 Man Sung Co Humanized antibodies reactive with l-selectin
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
JP2003501016A (ja) * 1999-05-27 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ａｄａｍのポリヌクレオチドおよびポリペプチド
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1970448A1 (en) 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
ATE416465T1 (de) 2005-06-30 2008-12-15 Borealis Tech Oy Überzug-schicht für energie- oder kommunikationskabel
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
CA2747534C (en) * 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
DK2509409T3 (en) 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CN103228130B (zh) * 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
PT3527070T (pt) 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci

Also Published As

Publication number Publication date
HK1201292A1 (en) 2015-08-28
AU2022206806A1 (en) 2022-08-18
MX343009B (es) 2016-10-21
DK2550363T3 (en) 2015-03-23
AU2012243291A1 (en) 2013-05-09
JP5866127B2 (ja) 2016-02-17
DK2738259T3 (da) 2020-02-17
SI4067496T1 (sl) 2023-07-31
PL4067496T3 (pl) 2023-07-31
ME02106B (me) 2015-10-20
JP2019187446A (ja) 2019-10-31
JP2018143250A (ja) 2018-09-20
ES2946169T3 (es) 2023-07-13
RS59661B1 (sr) 2020-01-31
KR101387377B1 (ko) 2014-04-21
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
SMT202300173T1 (it) 2023-07-20
JP2014110814A (ja) 2014-06-19
US20180345760A1 (en) 2018-12-06
SMT201900744T1 (it) 2020-01-14
CY1122205T1 (el) 2020-11-25
US20140213773A1 (en) 2014-07-31
AU2020201279A1 (en) 2020-03-12
IL261243B (en) 2019-08-29
DK2578688T4 (da) 2023-05-08
EP2738259A2 (en) 2014-06-04
US10905108B2 (en) 2021-02-02
DK2738258T3 (da) 2019-12-16
US20150201589A1 (en) 2015-07-23
EP2738258A2 (en) 2014-06-04
WO2012141798A1 (en) 2012-10-18
SG192933A1 (en) 2013-09-30
JP2022071051A (ja) 2022-05-13
EP2813573B1 (en) 2020-04-22
HK1174490A1 (en) 2013-06-14
JP2025032218A (ja) 2025-03-11
IL273986B (en) 2021-04-29
US20180346599A1 (en) 2018-12-06
SMT202000112T1 (it) 2020-05-08
US20210105984A1 (en) 2021-04-15
BR112013021771B1 (pt) 2022-11-16
DE14154967T1 (de) 2014-08-28
US9932408B2 (en) 2018-04-03
SG10201913160QA (en) 2020-03-30
CN103429746B (zh) 2016-05-11
SI2738259T1 (sl) 2020-06-30
AU2012243291B2 (en) 2015-07-09
ES2748832T3 (es) 2020-03-18
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
RS59661B2 (sr) 2023-06-30
EP2578688B2 (en) 2023-02-08
CY1122820T1 (el) 2021-05-05
DK2738258T4 (da) 2023-05-08
EP3744850A1 (en) 2020-12-02
IN2013CN07629A (enExample) 2015-08-07
FI4067496T3 (fi) 2023-05-24
IL268671B (en) 2020-05-31
NZ703609A (en) 2016-04-29
RS64280B1 (sr) 2023-07-31
EP2738258B2 (en) 2023-02-01
PT2738259T (pt) 2020-02-18
DK2578688T3 (da) 2019-10-28
MY172713A (en) 2019-12-11
SI2578688T1 (sl) 2019-11-29
PL2578688T3 (pl) 2020-05-18
CY1126091T1 (el) 2023-11-15
EP2738258A3 (en) 2014-09-24
JP2015107131A (ja) 2015-06-11
ES2770424T3 (es) 2020-07-01
RS59413B1 (sr) 2019-11-29
AU2015238806A1 (en) 2015-10-29
ME03537B (enExample) 2020-04-20
EP2813573A1 (en) 2014-12-17
BR112013021771A2 (pt) 2017-07-04
CN105861548B (zh) 2020-01-10
IL226727A (en) 2016-08-31
FI2738258T4 (fi) 2023-05-05
SG10201405135RA (en) 2014-10-30
CY1122459T1 (el) 2021-01-27
HRP20191895T1 (hr) 2020-01-10
ES2805364T3 (es) 2021-02-11
DK2738259T1 (da) 2014-11-24
US20210105985A1 (en) 2021-04-15
RS53880B1 (sr) 2015-08-31
RS59413B2 (sr) 2023-06-30
AU2017251802A1 (en) 2017-11-16
SI2578688T2 (sl) 2023-05-31
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
PL2550363T3 (pl) 2015-05-29
DK2578688T1 (da) 2014-11-24
US10577430B2 (en) 2020-03-03
HRP20230526T1 (hr) 2023-09-01
NZ612643A (en) 2015-06-26
US20120322108A1 (en) 2012-12-20
DE12716101T1 (de) 2013-05-08
LT4067496T (lt) 2023-06-12
MX2020009714A (es) 2020-10-07
US10905109B2 (en) 2021-02-02
RU2016109443A (ru) 2018-11-26
MX2013009649A (es) 2013-09-26
SMT201500061B (it) 2015-05-05
ZA201305998B (en) 2016-07-27
LT2738259T (lt) 2020-03-10
DK4067496T5 (da) 2024-07-22
MX375115B (es) 2025-03-06
NZ797720A (en) 2024-09-27
US9944716B2 (en) 2018-04-17
SI2738258T1 (sl) 2020-01-31
DK2813573T1 (da) 2015-01-12
HRP20200294T1 (hr) 2020-05-29
SI2738258T2 (sl) 2023-05-31
IL273986A (en) 2020-05-31
US20150210776A1 (en) 2015-07-30
US10072095B2 (en) 2018-09-11
EP2738259B1 (en) 2019-11-27
DE12192727T1 (de) 2013-07-11
PL2738258T3 (pl) 2020-08-24
US8642835B2 (en) 2014-02-04
SG10201913155QA (en) 2020-02-27
HUE046746T2 (hu) 2020-03-30
ES2532487T3 (es) 2015-03-27
EP2550363B1 (en) 2014-12-10
NZ776770A (en) 2023-03-31
EP2578688A1 (en) 2013-04-10
EP4067496A1 (en) 2022-10-05
ES2748832T5 (es) 2023-06-08
RU2013125717A (ru) 2014-12-10
HRP20191895T4 (hr) 2023-05-12
US20240306617A1 (en) 2024-09-19
IL268671A (en) 2019-10-31
JP2014507137A (ja) 2014-03-27
EP4067496B1 (en) 2023-03-29
PT2550363E (pt) 2015-03-16
LT2738258T (lt) 2020-01-10
EP2738259A3 (en) 2014-07-30
IL261243A (en) 2018-10-31
PL2738259T3 (pl) 2020-08-24
AU2025283466A1 (en) 2026-01-22
ME03732B (me) 2021-01-20
US20130254911A1 (en) 2013-09-26
CA2820824A1 (en) 2012-10-18
RU2016109443A3 (enExample) 2019-07-24
HRP20192311T4 (hr) 2023-05-12
HRP20192311T1 (hr) 2020-03-20
DK4067496T3 (da) 2023-06-26
CN103429746A (zh) 2013-12-04
US8697940B2 (en) 2014-04-15
EP2578688B1 (en) 2019-07-24
HRP20150262T1 (hr) 2015-04-10
PT2738258T (pt) 2019-12-10
US20180346598A1 (en) 2018-12-06
NZ718688A (en) 2017-07-28
PT4067496T (pt) 2023-06-07
RU2722373C2 (ru) 2020-05-29
HUE047687T2 (hu) 2020-05-28
FI2578688T4 (fi) 2023-05-05
CY1116301T1 (el) 2017-02-08
US12207628B2 (en) 2025-01-28
ES2758974T5 (es) 2023-06-08
US20180362663A1 (en) 2018-12-20
PL2578688T5 (pl) 2023-05-29
JP2016135143A (ja) 2016-07-28
KR20130116375A (ko) 2013-10-23
EP2738258B1 (en) 2019-09-25
NZ731926A (en) 2021-07-30
CN105861548A (zh) 2016-08-17
US10694725B2 (en) 2020-06-30
DE14154918T1 (de) 2014-08-21
AU2022206806B2 (en) 2025-10-02
SMT201900581T1 (it) 2019-11-13
DK2738258T1 (da) 2014-11-24
HUE024534T2 (hu) 2016-01-28
LT2578688T (lt) 2019-11-11
DE14176593T1 (de) 2015-03-05
RU2582261C2 (ru) 2016-04-20
RS59929B1 (sr) 2020-03-31
EP2550363A1 (en) 2013-01-30
HUE062552T2 (hu) 2023-11-28

Similar Documents

Publication Publication Date Title
BR112014008775A8 (pt) Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2020009714A (es) Ratones de una desintegrina y metaloproteasa 6 (adam6).
EP4635977A3 (en) Non-human animals having a humanized signal-regulatory protein gene
MY185881A (en) Non-human animals with modified immunoglobulin heavy chain sequences
GB2547587A (en) Transgenic mice
MX2022002117A (es) Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
WO2014093894A3 (en) Dna antibody constructs and method of using same
MX379533B (es) Ratones de cadena ligera universal humanizados.
EP4345163A3 (en) Genetic engineering of non-human animals for the production of chimeric antibodies
UA115321C2 (uk) Спосіб та комплект для аналізу ahasl генів у рослин
WO2014022702A3 (en) Methods and compositions for controlling gene expression by rna processing
MX2020010837A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
WO2013041845A3 (en) Animals, repertoires & methods for the production of human antibodies
NZ719881A (en) Plant cytochrome p450
EP3839055A3 (en) Yeast promoters for protein expression
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
DK2740797T3 (da) Protein med aktivitet til at fremme fedtsyreforlængelse, derfor kodende gen samt anvendelse deraf
WO2011128820A3 (en) Methods for the analysis of breast cancer disorders
WO2013023243A8 (en) Methods of controlling fructan synthesis in plants
NZ776960A (en) Restricted immunoglobulin heavy chain mice